Contact
Please use this form to send email to PR contact of this press release:
Tyme’s SM-88 to be included in Pancreatic Cancer Action Network’s (PanCAN’s) Novel “Precision Promise(SM)” Adaptive Phase II/III Pancreatic Cancer Trial Platform
TO: